Alpha-Galactosidase के लिए Bloating and Intestinal Gas
B संबंधित साक्ष्य कम से कम एक यादृच्छिक परीक्षण इसका समर्थन करता है, जिसके परिणाम अधिकतर सुसंगत हैं।Reduces gas symptoms from high-fiber foods containing raffinose/stachyose by 50-70%. Beano (alpha-galactosidase 300 GalU) is the most studied formulation.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dalpha\u002Dgalactosidase\u0026condition\u003Dbloating\u002Dand\u002Dgas';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
निष्कर्ष
Reduces gas symptoms from high-fiber foods containing raffinose/stachyose by 50-70%. Beano (alpha-galactosidase 300 GalU) is the most studied formulation.
Key Study Findings
Review
Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.
Dose: None
बनाम: None
Outcome: None
प्रभाव: None
None
जनसंख्या: None
Randomized Controlled Trial
Double-blind
A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal …
Dose: 1200 G
बनाम: placebo
Outcome: every 30 min during 7
प्रभाव: None
None
जनसंख्या: patients with ibs after three standardized
Other
n=17
FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument.
Dose: None
बनाम: no treatment
Outcome: None
प्रभाव: None
None
जनसंख्या: fabry disease but are often nonspecific
Randomized Controlled Trial
n=31
2.0 weeks
Double-blind
Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.
Dose: 300 GALU or 150 GALU
बनाम: Placebo (glucose)
Outcome: GI symptom severity on VAS
प्रभाव: None
pP0.006
जनसंख्या: IBS patients (Rome III, H2 producers)
Randomized Controlled Trial
n=125
4 weeks
Double-blind
Does oral α-galactosidase relieve irritable bowel symptoms?
Dose: alpha-galactosidase 600 GalU per meal
बनाम: placebo
Outcome: overall IBS symptom relief
प्रभाव: no significant difference vs placebo
>0.05
जनसंख्या: IBS patients
Case Reports
A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha …
Dose: 3.7nmol/mL/h
बनाम: None
Outcome: None
प्रभाव: None
None
जनसंख्या: patients
Key Statistics
4
अध्ययन
300
प्रतिभागी
↑
Positive
B
ग्रेड
Referenced Papers
International journal of …
2021
16 उद्धरण
Quality of life …
2021
14 उद्धरण
Neurogastroenterology and motility
2021
4 उद्धरण
The American journal …
2018
49 उद्धरण
Scandinavian journal of …
2016
17 उद्धरण
Clinical biochemistry
2015
18 उद्धरण
BMC gastroenterology
2013
12 उद्धरण
Digestive diseases and …
2007
45 उद्धरण
Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Other
Molecular genetics and …
2005
84 उद्धरण
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
सामान्य रूप से उपयोग की जाने वाली खुराकें
- general:
- 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods
- standardbeanodose:
- 300 GalU (2-3 tablets) with first bite of problem food
अधिकतम सीमा: No established upper limit; adjust per meal as needed
अनुसंधान में अध्ययन की गई खुराकें
| खुराक | अवधि | प्रभाव | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| 1200 G | -- | Neutral | -- |
| None | -- | Positive | 17 |
| 300 GALU or 150 GALU | 2.0 weeks | Positive | 31 |
| alpha-galactosidase 600 GalU per meal | 4 weeks | Neutral | 125 |
| 3.7nmol/mL/h | -- | Mixed | -- |
| None | 2 weeks | Positive | -- |
| 300 or 1200 GalU | -- | Positive | 8 |
सेवन का सर्वोत्तम समय: With the first bite of gas-producing food
Safety & Side Effects
रिपोर्ट किए गए दुष्प्रभाव
- ⚠ Generally very well-tolerated
- ⚠ Rare allergic reactions to mold-derived enzyme (Aspergillus source)
- ⚠ May cause mild GI discomfort in rare cases
ज्ञात अंतःक्रियाएँ
- ● Acarbose (alpha-galactosidase may counteract the blood sugar-lowering mechanism of acarbose; contraindicated for concurrent use)
- ● Miglitol (similar mechanism conflict as acarbose)
सहनीय अधिकतम सेवन: No established upper limit; adjust per meal as needed
कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।
Frequently Asked Questions
Does Alpha-Galactosidase help with Bloating and Intestinal Gas?
Based on 4 studies with 300 participants, there is moderate evidence from clinical studies that Alpha-Galactosidase may support Bloating and Intestinal Gas management. Our evidence grade is B (Good Evidence).
How much Alpha-Galactosidase should I take for Bloating and Intestinal Gas?
Studies have used various dosages. A commonly studied range is 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Alpha-Galactosidase?
Reported side effects may include Generally very well-tolerated, Rare allergic reactions to mold-derived enzyme (Aspergillus source), May cause mild GI discomfort in rare cases. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Alpha-Galactosidase and Bloating and Intestinal Gas?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
Related Evidence
इसके लिए अन्य सामग्री Bloating and Intestinal Gas
Alpha-Galactosidase अन्य स्वास्थ्य स्थितियों के लिए
References
- [1] Fabio Caputo et al.. Int J Environ Res Public Health. 2021. Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review. doi:10.3390/ijerph18063320 PubMed
- [2] Alan L Shields et al.. Qual Life Res. 2021. FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument. doi:10.1007/s11136-021-02847-9 PubMed
- [3] Lena Böhn et al.. Neurogastroenterol Motil. 2021. A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome … doi:10.1111/nmo.14094 PubMed
- [4] C J Tuck et al.. Am J Gastroenterol. 2018. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. doi:10.1038/ajg.2017.245 PubMed
- [5] Markku Hillilä et al.. Scand J Gastroenterol. 2016. Does oral α-galactosidase relieve irritable bowel symptoms? doi:10.3109/00365521.2015.1063156 PubMed
- [6] Antonino Tuttolomondo et al.. Clin Biochem. 2015. A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene. doi:10.1016/j.clinbiochem.2014.09.018 PubMed
- [7] Giovanni Di Nardo et al.. BMC Gastroenterol. 2013. Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. doi:10.1186/1471-230X-13-142 PubMed
- [8] Michele Di Stefano et al.. Dig Dis Sci. 2007. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. doi:10.1007/s10620-006-9296-9 PubMed
- [9] Maryam Banikazemi et al.. Mol Genet Metab. 2005. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. doi:10.1016/j.ymgme.2005.04.009 PubMed
- [10] T G Ganiats et al.. J Fam Pract. 1994. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. PubMed
FDA अस्वीकरण: इन कथनों का Food and Drug Administration द्वारा मूल्यांकन नहीं किया गया है। इस वेबसाइट पर उत्पादों और जानकारी का उद्देश्य किसी बीमारी का निदान, उपचार, इलाज या रोकथाम नहीं है। प्रस्तुत साक्ष्य ग्रेड प्रकाशित पीयर-रिव्यूड अनुसंधान के हमारे विश्लेषण पर आधारित हैं और चिकित्सा सलाह नहीं हैं। कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।